In vitro metabolism of piperaquine is primarily mediated by CYP3A4

References

• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–832.
   PubMed Web of Science ®Google Scholar
• Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. (2005). Piperaquine: A resurgent antimalarial drug. Drugs 65:75–87.
   PubMed Web of Science ®Google Scholar
• Donahue SR, Flockhart DA, Abernethy DR, Ko JW. (1997). Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 62:572–577.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2001). Guidance for industry: Bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed on: 28 July, 2009.
   Google Scholar
• German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. (2009). Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51:424–429.
   PubMed Web of Science ®Google Scholar
• Harper TW, Brassil PJ. (2008). Reaction phenotyping: Current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200–207.
   PubMed Web of Science ®Google Scholar
• Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. (2004). Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 57:253–262.
   PubMed Web of Science ®Google Scholar
• Jancová P, Anzenbacherová E, Papousková B, Lemr K, Luzná P, Veinlichová A, Anzenbacher P, Simánek V. (2007). Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035–2039.
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. (2005). Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249–256.
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Ilett KF, Mueller I, Siba P, Law I, Page-Sharp M, Lin E, Lammey J, Batty KT, Davis TM. (2008). Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother 52:237–243.
   PubMed Web of Science ®Google Scholar
• Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, Sandison TG, Homsy J, Tappero JW, Kamya MR, Dorsey G. (2009). Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 8:272.
   PubMed Web of Science ®Google Scholar
• Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. (2000). In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343–351.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Trager WF. (1993). Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649–656.
   PubMed Web of Science ®Google Scholar
• Lindegardh N, Annerberg A, White NJ, Day NP. (2008). Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 862:227–236.
   PubMed Web of Science ®Google Scholar
• Myint HY, Ashley EA, Day NP, Nosten F, White NJ. (2007). Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 101:858–866.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. (2007). Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: Proposed refinement and expansion of the “rank order” approach. Drug Metab Lett 1:31–35.
   PubMedGoogle Scholar
• Röshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton M. (2006). Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol 62:335–341.
   PubMed Web of Science ®Google Scholar
• Singhal P, Gaur A, Gautam A, Varshney B, Paliwal J, Batra V. (2007). Sensitive and rapid liquid chromatography/tandem mass spectrometric assay for the quantification of piperaquine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 859:24–29.
   PubMed Web of Science ®Google Scholar
• Slutsker L, Marston BJ. (2007). HIV and malaria: Interactions and implications. Curr Opin Infect Dis 20:3–10.
   PubMed Web of Science ®Google Scholar
• Störmer E, Brockmöller J, Roots I, Schmider J. (2000a). Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 151:312–320.
   PubMed Web of Science ®Google Scholar
• Störmer E, Roots I, Brockmöller J. (2000b). Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol 50:553–561.
   PubMed Web of Science ®Google Scholar
• Tarning J, Bergqvist Y, Day NP, Bergquist J, Arvidsson B, White NJ, Ashton M, Lindegårdh N. (2006). Characterization of human urinary metabolites of the antimalarial piperaquine. Drug Metab Dispos 34:2011–2019.
   PubMed Web of Science ®Google Scholar
• Tarning J, Lindegardh N. (2008). Quantification of the antimalarial piperaquine in plasma. Trans R Soc Trop Med Hyg 102:409–411.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2010). Guidelines for the treatment of malaria/World Health Organization. Available at: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf
   Google Scholar
• Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. (2002). Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30:314–318.
   PubMed Web of Science ®Google Scholar